Skip to main content
Premium Trial:

Request an Annual Quote

Affymetrix Posts Flat Q2 Revenues, Lowers Full-Year Forecast

This article has been updated from a previous version to include a stock quote.
NEW YORK (GenomeWeb News) - Affymetrix today lowered its full-year revenue forecast for the second time this year as it reported a 1.5 percent dip in second-quarter revenues to $86.9 million from $88.3 million in the comparable period of 2007.
 
Second-quarter product revenue rose 9.6 percent to $75 million from $68.4 million in the year-ago period. For the current quarter, array and reagent sales generated revenue of $68.9 million and instrument sales contributed $6.1 million. Affy said it shipped 22 GeneChip systems in the quarter.
 
Service revenue fell 25 percent to $9 million from $12 million in the second quarter of 2007, while royalties and other revenue dropped 63 percent to $2.9 million from $7.9 million.
 
Affy reported a net loss of $3.6 million, or $0.05 per diluted share, in the second quarter of 2008, which includes a pretax restructuring charge of $900,000, or $0.01 per diluted share. In the year-ago period, the company posted net income of $1.2 million or $0.02 per diluted share, which included a pretax restructuring charge of $1.8 million, or $0.03 per diluted share.
 
R&D spending was nearly flat at $19.6 million compared to $19.4 million in the second quarter of 2007, while SG&A costs decreased by 12 percent to $29.6 million from $33.6 million in the prior-year period.
 
The company also lowered its full-year forecast due to “predicted ongoing weakness” in pharmaceutical revenue. As a result, Affy now expects 2008 revenue to be in the range of $455 million to $460 million, including a $90 million payment from Illumina related to litigation between the firms.
 
The company had already lowered its revenue forecast for fiscal 2008 revenues to between $490 million and $510 million from an initial forecast of between $505 million and $525 million.
 
As of June 30, Affy had $326 million in cash and cash equivalents.
 
The company also disclosed today that it has purchased a company that is developing microparticle technology for use in diagnostic applications and that it has decided to close its West Sacramento, Calif., manufacturing facility.
 
In mid-morning Friday trading, Affy's shares were down 23 percent at $8.00.

The Scan

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.

Survey Sees Genetic Literacy on the Rise, Though Further Education Needed

Survey participants appear to have higher genetic familiarity, knowledge, and skills compared to 2013, though 'room for improvement' remains, an AJHG paper finds.

Study Reveals Molecular, Clinical Features in Colorectal Cancer Cases Involving Multiple Primary Tumors

Researchers compare mismatch repair, microsatellite instability, and tumor mutation burden patterns in synchronous multiple- or single primary colorectal cancers.

FarGen Phase One Sequences Exomes of Nearly 500 From Faroe Islands

The analysis in the European Journal of Human Genetics finds few rare variants and limited geographic structure among Faroese individuals.